Efficacy and safety of orally administered lentinula edodes mycelia extract for patients undergoing cancer chemotherapy: A pilot study

American Journal of Chinese Medicine

Volumn 39, Issue 3, 2011, Pages 451-459

  Yamaguchi, Yoshiyuki ^a,b   Miyahara, Eiji ^a   Hihara, Jun ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

Author keywords

Cancer; Chemotherapy; Immune Function; Lentinula Edodes Mycelia; Quality of Life

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; FOLIC ACID; IMMUNOSUPPRESSIVE ACID PROTEIN; IRINOTECAN; LENTINULA EDODES EXTRACT; TS 1; UFT; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ALOPECIA; ANOREXIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CELL ACTIVITY; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DRUG EFFICACY; DRUG SAFETY; ESOPHAGUS CANCER; FEMALE; HUMAN; HYPERPIGMENTATION; IMMUNE RESPONSE; MALE; MUCOSA INFLAMMATION; NATURAL KILLER CELL; NAUSEA; PILOT STUDY; QUALITY OF LIFE; STOMACH CANCER; T LYMPHOCYTE SUBPOPULATION;

ACTIVITIES OF DAILY LIVING; ADMINISTRATION, ORAL; AGED; BIOLOGICAL AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; MYCELIUM; NEOPLASM PROTEINS; PILOT PROJECTS; QUALITY OF LIFE; SHIITAKE MUSHROOMS; TREATMENT OUTCOME;

EID: 79957455347     PISSN: 0192415X     EISSN: 0192415X     Source Type: Journal    
DOI: 10.1142/S0192415X11008956     Document Type: Article

References (23)

1. Ahn, W.S., DJ. Kim, G.T. Chae, J.M. Lee, S.M. Bae, J.I. Sin, Y.W. Kim, S.E. Namkoong and LP. Lee. Natural killer cell activity and quality of life were improved by consumption of a mushroom extract, Agaricus blazei Murill Kyowa, in gynecological cancer patients undergoing chemotherapy. Int. J. Gynecol. Cancer 14: 589-594, 2004.
2. Cassileth, B.R. Complementary and alternative cancer medicine. J. Clin. Oncol. 17: 44-52, 1999. (Pubitemid 29519677)
3. Chihara, G., Y. Maeda, J. Hamuro, T. Sasaki and F. Fukuoka. Inhibition of mouse sarcoma 180 by polysaccharides from Lentinus edodes (Berk.) sing. Nature 222: 687-688, 1969.
4. Earl, H.M., L. Hiller, J.A. Dunn, S. Bathers, P. Harvey, A. Stanley, R.J. Grieve, R.K. Agrawal, I.N. Fernando, A.M. Brunt, K. McAdam, S. O'Reilly, D.W. Rea, D. Spooner and C.J. Poole. NEAT: National Epirubicin Adjuvant Trial\toxicity, delivered dose intensity and quality of life. Br. J. Cancer 99: 1226-1231, 2008.
5. Hazama, S., S. Watanabe, M. Ohashi, M. Yagi, M. Suzuki, K. Matsuda, T. Yamamoto, Y. Suga, T. Suga, S. Nakazawa and M. Oka. Efficacy of orally administered superfine dispersed Len-tinan ({beta}-l, 3-glucan) for the treatment of advanced colorectal cancer. Anticancer Res. 29: 2611-2617, 2009.
6. Hyodo, I., N. Amano, K. Eguchi, M. Narabayashi, J. Imanishi, M. Hirai, T. Nakano and S. Takashima. Nationwide survey on complementary and alternative medicine in cancer patients in Japan./. Clin. Oncol. 23: 2645-2654, 2005. (Pubitemid 46179453)
7. Kataoka, H., T. Shimura, T. Mizoshita, E. Kubota, Y. Mori, T. Mizushima, T. Wada, N. Ogasawara, S. Tanida, M. Sasaki, S. Togawa, H. Sano, Y. Hirata, M. Ikai, H. Mochizuki, K. Seno, S. Itoh, T. Kawai and T. Joh. Lentinan with S-l and paclitaxel for gastric cancer chemotherapy improve patient quality of life. Hepatogastroenterology 56: 547-550, 2009.
8. Katoh, R., S. Takenoshita, Y. Shimizu, S. Tanaka, Y. Yajima and Y. Nagamachi. Changes in serum soluble IL-2 receptors (sIL-2R) and immunosuppressive acidic protein (IAP) associated with chemotherapy for lung cancer. Anticancer Res. 17: 3787-3792, 1997. (Pubitemid 28014941)
9. Kawanishi, T., Y. Ikeda-Dantsuji and A. Nagayama. Effects of two basidiomycete species on interleukin 1 and interleukin 2 production by macrophage and T cell lines. Immunobiology 215: 516-520, 2010.
10. Kim, D.J., T.I. Kim, J.H. Suh, Y.S. Cho, S.K. Shin, J.K. Kang, N.K. Kim and W.H. Kim. Oral tegafur-uracil plus folinic acid versus intravenous 5-fluorouracil plus folinic acid as adjuvant chemotherapy of colon cancer. Yonsei. Med. J. 44: 665-675, 2003. (Pubitemid 37098888)
11. Kurihara, M., H. Shimizu, K. Tsuboi, K. Kobayashi, M. Murakami, K. Eguchi and K. Shimozuma. Development of quality of life questionnaire in Japan: quality of life assessment of cancer patients receiving chemotherapy. Psychooncology 8: 355-363, 1999. (Pubitemid 29417490)
12. Liu, M., J. Li, F. Kong, J. Lin and Y. Gao. Induction of immunomodulating cytokines by a new polysaccharide-peptide complex from culture mycelia of Lentinus edodes. Immunopharma-cology 40: 187-198, 1998. (Pubitemid 28522177)
13. Murta, E.F., J.M. de Andrade, R.P. Falcao and S. Bighetti. Lymphocyte subpopulations in patients with advanced breast cancer submitted to neoadjuvant chemotherapy. Tumori 86: 403-07, 2000.
14. Nakano, H., K. Namatame, H. Nemoto, H. Motohashi, K. Nishiyama and K. Kumada. A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group. Hepatogastroenterology 46: 2662-2668, 1999. (Pubitemid 29454163)
15. Paltiel, O., M. Avitzour, T. Peretz, N. Cherny, L. Kaduri, R.M. Pfeffer, N. Wagner and V. Soskolne. Determinants of the use of complementary therapies by patients with cancer. J. Clin. Oncol. 19: 2439-2448, 2001. (Pubitemid 32391215)
16. Riccardi, A., C. Tinelli, S. Brugnatelli, P. Pugliese, V. Giardina, M. Giordano, M. Danova, A. Richetti, S. Fava, E. Rinaldi, V. Fregoni, G Trotti and A. Poli. Doubling of the epirubicin dosage within the 5-fluorouracil, epirubicin and cyclophosphamide regimen: a prospective, randomized, multicentric study on antitumor effect and quality of life in advanced breast cancer. Int. J. Oncol. 16: 769-776, 2000.
17. Richardson, M.A., T. Sanders, J.L. Palmer, A. Greisinger and S.E. Singletary. Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology./. Clin. Oncol. 18: 2505-2514, 2000. (Pubitemid 30432515)
18. Shimizu, H., K. Tanaka, S. Ikeda, H. Sakamaki, S. Yajima, N. Ikegami and J. Murayama. [Utility-based evaluation of the quality of life of patient's with gastric cancer who receive chemotherapy\comparison of patients' quality of life between oral TS-1 and conventional injectable combination therapy] Yakugaku Zasshi 128: 783-793, 2008. (Pubitemid 351669203)
19. Sugano, N., Y. Hibino, Y. Choji and H. Maeda. Anticarcinogenic actions of water-soluble and alcohol-insoluble fractions from culture medium of Lentinus edodes mycelia. Cancer Lett. 17: 109-114, 1982. (Pubitemid 13171752)
20. Sugano, N., Y. Choji, Y. Hibino, S. Yasumura and H. Maeda. Anticarcinogenic action of an alcohol-insoluble fraction (LAP1) from culture medium of Lentinus edodes mycelia. Cancer Lett. 27: 1-6, 1985. (Pubitemid 15015763)
21. Takimoto, N., S. Sugawara, A. Iida, T. Sakakibara, K. Mori, M. Sugiura, K. Yamamura and M. Adachi. [Development of taste disorders following FOLFOX-FOLFIRI therapy and its effects on the QOL of patients with colorectal cancer] Gan To Kagaku Ryoho 36: 431-35, 2009.
22. Tamura, K., Y. Shibata, Y. Matsuda and N. Ishida. Isolation and characterization of an immunosuppressive acidic protein from ascitic fluids of cancer patients. Cancer Res. 41: 3244-3252, 1981. (Pubitemid 11035548)
23. Wijayahadi, N., M.R. Haron, J. Stanslas and Z. Yusuf. Changes in cellular immunity during chemotherapy for primary breast cancer with anthracycline regimens. J. Chemother. 19: 716-723, 2007. (Pubitemid 351212023)